Baricitinib in the Treatment of Older Adults with COVID-19 – a Single Center Study

This study investigates the impact of baricitinib, a drug used for treating COVID-19, on both elderly and younger patients. The single-center cohort study analyzed 88 hospitalized COVID-19 patients, 34 of whom were over 65 years old. The results showed that baricitinib was safe and well-tolerated among the elderly population, with no adverse effects observed. Moreover, the length of hospitalization did not differ significantly between age groups. Specific laboratory findings in the elderly group indicated physiological differences, but overall, baricitinib proved to be an effective therapeutic option for moderate to severe COVID-19 cases across all age groups.